{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:57:08Z","timestamp":1792083428135,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.nbd.2010.07.004","type":"journal-article","created":{"date-parts":[[2010,7,22]],"date-time":"2010-07-22T08:50:30Z","timestamp":1279788630000},"page":"444-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: Implications for early intervention on disease progression"],"prefix":"10.1016","volume":"40","author":[{"given":"Almas","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothi K.","family":"Mallajosyula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Rane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2010.07.004_bb0005","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1523\/JNEUROSCI.4269-04.2005","article-title":"Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease","volume":"25","author":"Andrews","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.07.004_bb0010","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20855","article-title":"Striatal subregional 6-[18F]fluoro-l-dopa uptake in early Parkinson's disease: a two-year follow-up study","volume":"21","author":"Bruck","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2010.07.004_bb0015","doi-asserted-by":"crossref","first-page":"13997","DOI":"10.1523\/JNEUROSCI.3885-07.2007","article-title":"Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration","volume":"27","author":"Chinta","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.07.004_bb0020","first-page":"89","article-title":"The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence","volume":"19","author":"Cohen","year":"1983","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.nbd.2010.07.004_bb0025","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1073\/pnas.94.10.4890","article-title":"Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow","volume":"94","author":"Cohen","year":"1997","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.nbd.2010.07.004_bb0030","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/(SICI)1096-8628(19970418)74:2<154::AID-AJMG7>3.0.CO;2-U","article-title":"Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson disease","volume":"74","author":"Costa","year":"1997","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.nbd.2010.07.004_bb0035","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-211-73574-9_4","article-title":"Endogenous oxidized indoles share inhibitory potency against [3H]isatin binding in rat brain","volume":"72","author":"Crumeyrolle-Arias","year":"2007","journal-title":"J. Neural Transm. Suppl."},{"issue":"Pt 5","key":"10.1016\/j.nbd.2010.07.004_bb0040","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson's disease: substantia nigra regional selectivity","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2010.07.004_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01249185","article-title":"The effect of age on the activity and molecular properties of human brain monoamine oxidase","volume":"49","author":"Fowler","year":"1980","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.nbd.2010.07.004_bb0050","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1212\/WNL.47.6_Suppl_3.137S","article-title":"Pharmacology of selegiline","volume":"47","author":"Gerlach","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2010.07.004_bb0055","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/mds.10268","article-title":"Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease","volume":"17","author":"Goudreau","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2010.07.004_bb0060","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/mds.870080417","article-title":"Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease","volume":"8","author":"Hauser","year":"1993","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2010.07.004_bb0065","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1212\/WNL.58.9.1381","article-title":"MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD","volume":"58","author":"Hernan","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2010.07.004_bb0070","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.410370318","article-title":"An allelic association study of monoamine oxidase B in Parkinson's disease","volume":"37","author":"Ho","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2010.07.004_bb0075","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0006-8993(92)90473-M","article-title":"The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL\/6 mice: a critical reassessment","volume":"572","author":"Irwin","year":"1992","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2010.07.004_bb0080","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1471-4159.2006.04265.x","article-title":"Green tea polyphenol (\u2212) -epigallocatechin-3-gallate promotes the rapid protein kinase C- and proteasome-mediated degradation of Bad: implications for neuroprotection","volume":"100","author":"Kalfon","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2010.07.004_bb0085","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0896-6273(03)00126-0","article-title":"Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease","volume":"37","author":"Kaur","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2010.07.004_bb0090","doi-asserted-by":"crossref","first-page":"46432","DOI":"10.1074\/jbc.M306378200","article-title":"Oxidative alpha-ketoglutarate dehydrogenase inhibition via subtle elevations in monoamine oxidase B levels results in loss of spare respiratory capacity: implications for Parkinson's disease","volume":"278","author":"Kumar","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2010.07.004_bb0095","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/ana.410330406","article-title":"Association of a monoamine oxidase B allele with Parkinson's disease","volume":"33","author":"Kurth","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2010.07.004_bb0100","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1073\/pnas.79.20.6385","article-title":"Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons","volume":"79","author":"Levitt","year":"1982","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.nbd.2010.07.004_bb0105","first-page":"171","article-title":"Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment","volume":"43","author":"LeWitt","year":"1994","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.nbd.2010.07.004_bb0110","doi-asserted-by":"crossref","first-page":"e1616","DOI":"10.1371\/journal.pone.0001616","article-title":"MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology","volume":"3","author":"Mallajosyula","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nbd.2010.07.004_bb0115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mnfr.200500156","article-title":"Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders","volume":"50","author":"Mandel","year":"2006","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.nbd.2010.07.004_bb0120","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2967\/jnumed.107.041947","article-title":"18F-DOPA PET and PET\/CT","volume":"48","author":"Nanni","year":"2007","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.nbd.2010.07.004_bb0125","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1523\/JNEUROSCI.16-13-04135.1996","article-title":"Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine","volume":"16","author":"Nirenberg","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.07.004_bb0130","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1523\/JNEUROSCI.16-02-00436.1996","article-title":"The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons","volume":"16","author":"Nirenberg","year":"1996","journal-title":"J. Neurosci."},{"issue":"Suppl 1","key":"10.1016\/j.nbd.2010.07.004_bb0135","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/mds.870080503","article-title":"A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease","volume":"8","author":"Olanow","year":"1993","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2010.07.004_bb0140","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ana.410430309","article-title":"Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group","volume":"43","author":"Parkinson's Study group","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2010.07.004_bb0145","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/BF02284846","article-title":"Ultrastructural view of central catecholaminergic transmission: immunocytochemical localization of synthesizing enzymes, transporters and receptors","volume":"25","author":"Pickel","year":"1996","journal-title":"J. Neurocytol."},{"key":"10.1016\/j.nbd.2010.07.004_bb0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ajmg.b.30293","article-title":"[18F]FDOPA PET as an endophenotype for Parkinson's disease linkage studies","volume":"141B","author":"Racette","year":"2006","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.nbd.2010.07.004_bb0155","first-page":"111","article-title":"Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl","volume":"45","author":"Riederer","year":"1987","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.nbd.2010.07.004_bb0160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1385\/ENDO:21:1:81","article-title":"Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both?","volume":"21","author":"Saunders-Pullman","year":"2003","journal-title":"Endocr."},{"key":"10.1016\/j.nbd.2010.07.004_bb0165","first-page":"89","article-title":"Age-related changes on MAO in Bl\/C57 mouse tissues: a quantitative radioautographic study","volume":"41","author":"Saura","year":"1994","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.nbd.2010.07.004_bb0170","first-page":"391","article-title":"DATATOP-study: significance of its results in the treatment of Parkinson's disease","volume":"46","author":"Schneider","year":"1995","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.nbd.2010.07.004_bb0175","first-page":"122","article-title":"Polymorphism of MAO-B gene and NAD(P)H: quinone oxidoreductase gene in Parkinson's disease","volume":"18","author":"Shao","year":"2001","journal-title":"Zhonghua Yi. Xue.Yi. Chuan Xue. Za Zhi"},{"issue":"Suppl 1","key":"10.1016\/j.nbd.2010.07.004_bb0180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000116869","article-title":"An interim report of the effect of selegiline (l-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group","volume":"32","author":"Shoulson","year":"1992","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.nbd.2010.07.004_bb0185","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1212\/WNL.55.4.533","article-title":"Variability and validity of polymorphism association studies in Parkinson's disease","volume":"55","author":"Tan","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2010.07.004_bb0190","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0076-6879(96)64044-0","article-title":"Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines","volume":"264","author":"Trounce","year":"1996","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.nbd.2010.07.004_bb0195","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1046\/j.1523-1755.2001.00468.x","article-title":"Dopamine induces ERK activation in renal epithelial cells through H2O2 produced by monoamine oxidase","volume":"59","author":"Vindis","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.nbd.2010.07.004_bb0200","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1126\/science.3875898","article-title":"Distinct monoamine oxidase A and B populations in primate brain","volume":"230","author":"Westlund","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.nbd.2010.07.004_bb0205","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0306-4522(88)90250-3","article-title":"Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem","volume":"25","author":"Westlund","year":"1988","journal-title":"Neuroscience"},{"issue":"Suppl 1","key":"10.1016\/j.nbd.2010.07.004_bb0210","first-page":"S287","article-title":"Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness","volume":"147","author":"Youdim","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2010.07.004_bb0215","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/jnnp.70.2.229","article-title":"Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease","volume":"70","author":"Zhou","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996110002287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996110002287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T18:40:01Z","timestamp":1707590401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996110002287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0969996110002287"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2010.07.004","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: Implications for early intervention on disease progression","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2010.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}